Compare Stocks: RAPT, ORKA, KNSA, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals International	$78.23 +0.3%	$75.25	$35.20 ▼ $82.94	$6.05B	0.09	516,462 shs	403,905 shs
MIRM Mirum Pharmaceuticals	$91.07 -0.3%	$102.68	$63.23 ▼ $130.00	$5.89B	0.49	846,670 shs	1,090 shs
ORKA Oruka Therapeutics	$93.21 -1.4%	$96.72	$14.89 ▼ $115.51	$6.30B	-0.34	1.09 million shs	23,287 shs
RAPT Rapt Therapeutics	$58.02	$57.90	$5.67 ▼ $58.02	$1.61B	0.49	4.25 million shs	N/A

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals International	-0.17%	+3.79%	-1.30%	+31.91%	+116.19%
MIRM Mirum Pharmaceuticals	-0.66%	-2.67%	-5.11%	-20.37%	+23.62%
ORKA Oruka Therapeutics	+1.25%	+2.55%	-12.42%	+15.07%	+452.37%
RAPT Rapt Therapeutics	0.00%	0.00%	0.00%	0.00%	+188.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals International	$78.23 +0.3%	$75.25	$35.20 ▼ $82.94	$6.05B	0.09	516,462 shs	403,905 shs
MIRM Mirum Pharmaceuticals	$91.07 -0.3%	$102.68	$63.23 ▼ $130.00	$5.89B	0.49	846,670 shs	1,090 shs
ORKA Oruka Therapeutics	$93.21 -1.4%	$96.72	$14.89 ▼ $115.51	$6.30B	-0.34	1.09 million shs	23,287 shs
RAPT Rapt Therapeutics	$58.02	$57.90	$5.67 ▼ $58.02	$1.61B	0.49	4.25 million shs	N/A

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals International	-0.17%	+3.79%	-1.30%	+31.91%	+116.19%
MIRM Mirum Pharmaceuticals	-0.66%	-2.67%	-5.11%	-20.37%	+23.62%
ORKA Oruka Therapeutics	+1.25%	+2.55%	-12.42%	+15.07%	+452.37%
RAPT Rapt Therapeutics	0.00%	0.00%	0.00%	0.00%	+188.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	12.02% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.31	50.25% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$133.00	40.67% Upside
RAPT Rapt Therapeutics	2.18	Hold	$56.57	-2.50% Downside

Current Analyst Ratings Breakdown

Latest RAPT, ORKA, KNSA, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ORKA Oruka Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/27/2026	MIRM Mirum Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$137.00
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/11/2026	ORKA Oruka Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
8/11/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
8/11/2026	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$151.00
8/6/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/6/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$123.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KNSA Kiniksa Pharmaceuticals International	$677.56M	8.98	$0.79 per share	98.43	$7.44 per share	10.48
MIRM Mirum Pharmaceuticals	$521.31M	11.38	$0.05 per share	1,804.66	$6.12 per share	14.93
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	$11.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	80.41	37.68	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$11.06	N/A	N/A	N/A	N/A	-61.81%	-54.73%	N/A

Latest RAPT, ORKA, KNSA, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
ORKA Oruka Therapeutics	N/A	38.51	38.51
RAPT Rapt Therapeutics	N/A	12.04	12.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KNSA Kiniksa Pharmaceuticals International	53.95%
MIRM Mirum Pharmaceuticals	N/A
ORKA Oruka Therapeutics	56.44%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
KNSA Kiniksa Pharmaceuticals International	51.98%
MIRM Mirum Pharmaceuticals	8.32%
ORKA Oruka Therapeutics	23.49%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A
RAPT Rapt Therapeutics	80	27.71 million	27.06 million	Optionable

RAPT, ORKA, KNSA, and MIRM Headlines

Recent News About These Companies

FTC drug divestiture policy may reduce competition, study finds

April 10, 2026 | news-medical.netN

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

March 21, 2026 | fool.com

RAPT Therapeutics Completes Acquisition and Transitions to Private Ownership

March 18, 2026 | theglobeandmail.com

This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share

March 15, 2026 | fool.com

GSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth Story

March 7, 2026 | finance.yahoo.com

GSK reached out to buyout target's big shareholder before talking to senior leaders

March 5, 2026 | bizjournals.com

Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp 3 Month Share Price Surge

March 1, 2026 | finance.yahoo.com

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges

February 25, 2026 | fool.com

GSK to buy Canada's 35Pharma for $950 million

February 25, 2026 | finance.yahoo.com

GSK’s $2.2 billion RAPT acquisition shows how a constrained immunology use case can become adoption ready and commercially attractive

February 10, 2026 | businessweekly.co.ukB

The Pharma Letter M&A round-up - January 2026

February 6, 2026 | thepharmaletter.comT

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

February 5, 2026 | businesswire.com

RAPT Therapeutics (RAPT) price target decreased by 12.94% to 54.97

February 4, 2026 | msn.com

Jan. 27 Business Watch: Vioneo moves project to China; GSK to buy Rapt Therapeutics for $2.2 billion

January 28, 2026 | cen.acs.orgC

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

January 27, 2026 | globenewswire.com

Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge

January 23, 2026 | finance.yahoo.com

Biggest Market Mover: RAPT Therapeutics Stock Soars After GSK $2.2B Acquisition Deal

January 21, 2026 | finance.yahoo.com

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

January 21, 2026 | businesswire.com

GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout

January 21, 2026 | zacks.com

Rapt Therapeutics (RAPT) Stock: Pharma Giant GSK Pays $2.2 Billion for Biotech

January 21, 2026 | blockonomi.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, ORKA, KNSA, and MIRM Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$78.22 +0.23 (+0.29%)

As of 09:37 AM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Mirum Pharmaceuticals NASDAQ:MIRM

$91.07 -0.32 (-0.35%)

As of 09:37 AM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oruka Therapeutics NASDAQ:ORKA

$93.21 -1.34 (-1.41%)

As of 09:37 AM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Rapt Therapeutics NASDAQ:RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPT, ORKA, KNSA, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPT, ORKA, KNSA, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPT, ORKA, KNSA, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, ORKA, KNSA, and MIRM Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

Rapt Therapeutics NASDAQ:RAPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPT, ORKA, KNSA, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPT, ORKA, KNSA, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPT, ORKA, KNSA, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPT, ORKA, KNSA, and MIRM Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Mirum Pharmaceuticals NASDAQ:MIRM

Oruka Therapeutics NASDAQ:ORKA

Rapt Therapeutics NASDAQ:RAPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools